Everest Medicines announced that its New Drug Application for Nefecon® has been accepted for review by the Taiwan Food and Drug Administration for the treatment of primary immunoglobulin A nephropathy in adult patients.
Everest Medicines announced that its New Drug Application for Nefecon® has been accepted for review by the Taiwan Food and Drug Administration for the treatment of primary immunoglobulin A nephropathy in adult patients.